UNIGE document Scientific Article
previous document  unige:112376  next document
add to browser collection
Title

Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP)

Authors
Koulla-Shiro, Sinata
Sawadogo, Adrien Bruno
Ndour, Cheik Tidiane
Eymard-Duvernay, Sabrina
Mbouyap, Pretty Rosereine
Ayangma, Liliane
Zoungrana, Jacques
show hidden authors show all authors [1 - 20]
Published in The Lancet HIV. 2017, vol. 4, no. 9, p. e384-e392
Abstract Despite satisfactory efficacy of WHO-recommended second-line antiretroviral treatment for patients with HIV in low-income countries, the need for simplified, low-cost, and less-toxic maintenance strategies remains high. We compared boosted protease inhibitor monotherapy with dual therapy with boosted protease inhibitor plus lamivudine in patients on second-line antiretrovial therapy (ART).
Keywords AdultAfrica South of the Sahara/epidemiologyAnti-HIV Agents/administration & dosage/economics/therapeutic useAntiretroviral TherapyHighly Active/methodsCD4 Lymphocyte CountCameroon/epidemiologyDrug TherapyCombination/methodsFemaleHIV Infections/drug therapy/epidemiology/virologyHIV Protease Inhibitors/administration & dosage/therapeutic useHIV-1HumansLamivudine/administration & dosage/therapeutic useMaleMiddle AgedReverse Transcriptase Inhibitors/administration & dosage/therapeutic useSenegal/epidemiologyViral Load/drug effects
Identifiers
PMID: 28566227
Note Sous-titre : a multicentre, randomised, parallel, open-label, superiority trial.
Full text
Article (Published version) (626 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Structures
Research group VIH/SIDA (930)
Citation
(ISO format)
CIAFFI, Laura et al. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP). In: The Lancet HIV, 2017, vol. 4, n° 9, p. e384-e392. doi: 10.1016/S2352-3018(17)30069-3 https://archive-ouverte.unige.ch/unige:112376

140 hits

0 download

Update

Deposited on : 2018-12-18

Export document
Format :
Citation style :